APL 2006
Alternative Names: APL-2006Latest Information Update: 28 Mar 2023
Price :
$50 *
At a glance
- Originator Apellis Pharmaceuticals
- Class Eye disorder therapies
- Mechanism of Action Complement C3 inhibitors; Vascular endothelial growth factors inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Dry age-related macular degeneration; Wet age-related macular degeneration
Most Recent Events
- 28 Mar 2023 Apellis Pharmaceuticals has patent protection for APL 2006 and APL 1030
- 09 Aug 2021 Apellis Pharmaceuticals plans to submit IND for Dry age related macular degeneration and Wet age related macular degeneration in the first half of 2023
- 30 Jun 2021 Preclinical trials in Dry age-related macular degeneration in USA (unspecified route)